Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BDRX 
Biodexa Pharmaceticals (BDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BDRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $182.77
1 Year Target Price $182.77
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.48M USD | Price to earnings Ratio - | 1Y Target Price 182.77 |
Price to earnings Ratio - | 1Y Target Price 182.77 | ||
Volume (30-day avg) 1 | Beta 0.98 | 52 Weeks Range 5.33 - 137.50 | Updated Date 08/29/2025 |
52 Weeks Range 5.33 - 137.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -134.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.41% | Return on Equity (TTM) -88.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2119202 | Price to Sales(TTM) 0.58 |
Enterprise Value 2119202 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 619523 | Shares Floating 25152188016 |
Shares Outstanding 619523 | Shares Floating 25152188016 | ||
Percent Insiders 0.95 | Percent Institutions 6.25 |
Upturn AI SWOT
Biodexa Pharmaceticals
Company Overview
History and Background
Biodexa Pharmaceuticals PLC, formerly known as Nucana Biomed Limited, focuses on developing and commercializing products for use in oncology and supportive care. Founded in 2008, the company has evolved through various strategic shifts, including a name change reflecting its expanded focus. Its milestones include clinical trial advancements and strategic partnerships to enhance its product pipeline.
Core Business Areas
- Oncology: Development of novel therapies for cancer treatment, with a focus on improving drug delivery and efficacy.
- Supportive Care: Development of treatments to mitigate side effects of cancer therapy and improve patient quality of life.
Leadership and Structure
The leadership team consists of experienced professionals in pharmaceutical development, clinical research, and business management. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- MTX110: A formulation of methotrexate for intratumoral treatment of recurrent head and neck cancer. MTX110 is designed to be delivered directly into tumors via convection-enhanced delivery (CED), bypassing the blood-brain barrier. Phase 3 clinical trials are underway. Competitors include standard chemotherapies and radiation therapies.
- BTD-001: In development, designed to improve drug delivery and efficacy for difficult-to-treat cancers. Competition depends on specific indication and delivery method.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The oncology market is driven by increasing cancer incidence and advancements in personalized medicine.
Positioning
Biodexa Pharmaceticals aims to establish a niche in targeted cancer therapies and supportive care by leveraging innovative drug delivery technologies. The company seeks to improve treatment outcomes and patient experiences through its specialized products.
Total Addressable Market (TAM)
The global oncology drug market is projected to reach hundreds of billions of dollars. Biodexa focuses on specific niches within this market, such as recurrent head and neck cancer, addressing unmet needs with targeted therapies.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technology
- Focus on unmet medical needs
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small market capitalization
- Dependence on few key products
Opportunities
- Expansion into new indications
- Potential for strategic acquisitions
- Increasing demand for targeted cancer therapies
- Favorable regulatory pathways for orphan drugs
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Biodexa Pharmaceticals faces significant competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative drug delivery technologies and focus on niche markets. However, it must overcome financial limitations and clinical trial risks to succeed.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by fluctuations due to clinical trial outcomes and financing activities.
Future Projections: Future growth projections depend on the successful development and commercialization of MTX110 and other pipeline products. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing MTX110 through Phase 3 clinical trials and exploring new partnerships to expand the product pipeline.
Summary
Biodexa Pharmaceuticals is a small pharmaceutical company focusing on innovative drug delivery technologies for oncology. While its targeted approach and experienced management are strengths, it faces significant challenges, including limited financial resources and competition from larger players. The company's future hinges on the successful development and commercialization of its lead product, MTX110, and other pipeline assets. Investors should carefully assess the clinical trial risks and financial stability before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market data is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodexa Pharmaceticals
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-12-07 | CEO, CFO, Company Secretary & Director Mr. Stephen Anthony Stamp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.biodexapharma.com |
Full time employees 13 | Website https://www.biodexapharma.com | ||
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.